The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
The potential clinical significance of CDK6 inhibitors in leukemia
Iris Uras, PhD of the University of Veterinary Medicine, Vienna, Austria talks about the potential clinical significance of targeted CDK6 inhibitors in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL) or acute lymphoblastic leukemia (ALL). The results of a study on the use of the CDK4/CDK6 inhibitor palbociclib for the treatment of FLT3-ITD+ acute myeloid leukemia (AML) cells were published in Blood. Targeted CDK6 inhibitors have the potential to suppress the relapse of the FLT3-ITD+ clone in AML once remission has been achieved. Further, they may help patients with a high allelic ratio to achieve remission. Dr Uras also discusses how the simultaneous targeting for CDK6 and FLT3, results in the highly effective killing of wild-type FLT3 mutated leukemic cells. Recorded via video conference.
Article available here: http://www.bloodjournal.org/content/early/2016/04/20/blood-2015-11-683581
